Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese

Table 5

Safety outcome for VTE in all patients.

Safety outcome	Rivaroxaban (N = 86)
	Event rate (%)	value
Major bleeding
BMI <25	1/16 = 6.3	1.000
BMI ≥25	4/69 = 5.8
BMI <30	3/38 = 7.9	0.653
BMI ≥30	2/47 = 4.3
Clinically relevant nonmajor bleeding (CRNMB)
BMI <25	2/16 = 12.5	1.000
BMI ≥25	8/69 = 11.6
BMI <30	4/38 = 10.5	1.000
BMI ≥30	6/47 = 12.8
Combined bleeding
BMI <25	3/16 = 18.8	1.000
BMI ≥25	12/69 = 17.4
BMI <30	7/38 = 18.4	0.866
BMI ≥30	8/48 = 16.7

Combined bleeding is a composite outcome of major bleeding and clinically relevant nonmajor bleeding. Chi-square and Fisher’s exact tests for safety outcomes (major bleeding, CRNMB, and combined bleeding) in patients with BMI <25 versus ≥25 in the VTE cohort.